senthil kumar

Algorithm for the diagnosis of primary aHUS go.nature.com/3uHusCb

Excellent algorithm for diagnosis & treat T cell leukemia #T-PLL , #ATLL , #T-LGL , #Sezary

Sir, there is a Govt Hospital in Tamilnadu, everywhere near u, for ailments such as 'simple fever'. In villages there r PHCs. In cities, towns there r upgraded UPHCs near ur house. You will get immediate, dignified treatment, tests and drugs( if deemed necessary ) free. When my close relative developed life-threatening neuroglycopenia recently, I got him admitted to Govt Royapettah Hospital. The treatment was prompt, & carried out in the middle of the night by highly qualified superspecialists. I personally feel all Chennaites shd visit Govt Kalaignar Hospital, atleast once as a visitor, to appreciate the warmth of the reception, the luxurious interiors, aesthetics, the kind staff,& the nature of inpatient & outpatient treatment. Personally feel it is at par or better than any 7-star private hospital in Chennai.

Cholangiocarcinoma 2026: status quo, unmet needs and priorities nature.com/articles/s4157… #liverpath

Advances in the management of metastatic gastric cancer: current strategies and emerging therapeutics | Nature Reviews Clinical Oncology nature.com/articles/s4157…

Advances in the management of metastatic gastric cancer: current strategies and emerging therapeutics Great review👇 nature.com/articles/s4157…

Time for another NET talk - this time on sequencing of systemic therapy. Another excellent @MayoMedEd offering. If you are looking for a good course in pretty much anything in Med Ed, check them out. They have a huge selection of quality courses, not just in oncology. So how to we select initial therapy for advanced NETs when resection or other regional therapy is not a good option...? Below are some thoughts, as always open to criticism and and comments (snarky comments also welcomed if you feel so inclined...). Come join us for future Mayo Clinic conferences!

Emerging landscape of KRAS inhibitors in cancer treatment @Cancer_Cell doi.org/10.1016/j.ccel… 👏great review 👉Tsunami of new drugs and oppertunities @myESMO @ASCO

EGFR mutation in NSCLC and why exon 20 insertion is different . #oncology #Medtwitter

A simplified ADCs summary 💊 #Oncology #MedTwitter

40 years ago, a young physician submitted a paper reporting on the alteration of a gene called HER2/neu to Science. He didn’t know that it was the beginning of one of the most remarkable scientific stories of the human kind, which would eventually impact the lives of COUNTLESS patients with cancer — first via mABs, then through ADCs, bsAbs and beyond. Unforgettable Keynote presentation by Dennis Slamon at #MBCC26.

In resectable high-risk intrahepatic cholangiocarcinoma, neoadjuvant GOLP refimen (gemcitabine–oxaliplatin, lenvatinib, and an anti–programmed death 1 antibody) before surgery doubled median event-free survival (18.0 vs 8.7 mo; P<0.001). OS still immature. Grade ≥3 AEs 26%. @NEJM @OncoAlert

Oncology 2026 WBC Growth Factors: ASCO Guideline Update ascopubs.org/doi/10.1200/JC…

ASCO Educational Book Neoadjuvant Systemic Therapy in Kidney and Bladder Cancer: Current Evidence and Emerging Paradigms (The results were not included in this paper; however, based on EV-304, we now know that EV + pembrolizumab is also a highly effective regimen in cisplatin-eligible patients) ascopubs.org/doi/10.1200/ED…

Big news in Cholangiocarcinoma, an aggressive GI cancer with limited tx options and rapid functional decline. In a 🇨🇳 trial, neoadj GOLP (gemcitabine, oxaliplatin, lenvatinib, toripalimab)- surgery and adj capecitabine improved EFS, with trend favoring OS (NS) nejm.org/doi/full/10.10…

📘Neoadjuvant Systemic Therapy in Kidney and Bladder Cancer @ASCO Educational Book 👉ascopubs.org/doi/pdf/10.120… #cancer #oncology #MedX @OncoAlert

Ovarian cancer new comprehensive Primer in Nature Reviews Disease Primers Scott CL, Banerjee S, Joly F, Lee J-M, Mukhopadhyay A, Tan DS, Kohn EC Natre Rev Dis Primers (2026) 🔹 Epithelial ovarian cancer (EOC) is biologically heterogeneous, with distinct histologies, molecular drivers and prognoses. 🔹 Most high-grade serous ovarian cancers originate from the fallopian tube fimbria. 🔹 No effective screening → late-stage diagnosis remains common. 💊 Standard management: • Optimal cytoreductive surgery • Carboplatin + paclitaxel • ± Anti-angiogenic therapy • PARP inhibitors in 1L for HRD/BRCA tumors 📌 Immunotherapy has shown limited efficacy so far, highlighting the need for biomarker-driven trials. 🔗 nature.com/articles/s4157… @myESMO @SGO_org @ESGO_society @NaturePortfolio @TheLancet #OvarianCancer #GynecologicOncology #PrecisionOncology #PARPInhibitors #OncoTwitter

Just in: Good news for the myeloma field. FDA approves teclistamab plus daratumumab (Tec-Dara) combination for myeloma for patients who have had at least one prior line of therapy. Note: Always use Tec-Dara with monthly IVIG. It’s not optional. That was fast! And this is unprecedented curve is why.

Ovarian cancer nature.com/articles/s4157…